December S&P 500 futures (ESZ23) are up +0.04%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.05% this morning as market participants geared up for a flurry of U.S. economic data while also...
Janux Therapeutics, Inc. (JANX) delivered earnings and revenue surprises of 14.29% and 21.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 17.02% and 4.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Gritstone bio Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 3.23% and 38.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -7.02% and 112.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 10.26% and 22.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
-- Expert in virology, immunology and vaccine development’s appointment effective August 12 --...
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 15% and 117.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
EMERYVILLE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...